Latest research on Lisinopril

Lisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.

Latest findings

As for specific medications, Aspirin, Metoprolol, Lisinopril, and Furosemide were the most common. [source, 2016]
The first bradykinin potentiating peptide, isolated from the Bothrops jararaca, venom became the precursor of today's most commonly used antihypertensive drugs like Captopril or Lisinopril [11, 12]. [source, 2016]
For primary outcomes (all-cause mortality, stroke volume, and ejection fraction), only Lisinopril was associated with a higher incidence of all-cause mortality compared with placebo or Ramipril. [source, 2016]
An increase in all-cause mortality combined with a limited effect on reducing systolic and diastolic blood pressure made Lisinopril the worest choice among the ACE inhibitors evaluated. [source, 2016]
Here we show that MSC prevent fibrogenic kidney injury in experimental UUO and compare their effects with those of Lisinopril, an ACEi. [source, 2016]
ACEi: 8 rats received Lisinopril in the drinking water (100 mg/L) from days 1 to 21. [source, 2016]
A 54-year-old African-American male with hypertension treated with multiple medications, including Lisinopril 80 mg daily, Amlodipine 10 mg daily, Hydralazine 50 mg trice daily, and Clonidine 0.2 mg twice daily; type 2 diabetes controlled with glimepiride 1 mg daily; and stage 4 CKD due to diabetic kidney disease was evaluated in nephrology office during routine follow-up visit. [source, 2016]
Because patient's weight and blood pressure were significantly lower than the usual for him with no signs of infection, the presence of volume depletion was suspected and Lisinopril was discontinued. [source, 2016]
While continuing to hold Lisinopril and linagliptin, SCr improved to 3.4 mg/dL in 10 days and remained stable for the next 2 months. [source, 2016]
Due to chronic proteinuria, a low dose of Lisinopril at 10 mg daily was restarted. [source, 2016]